Literature DB >> 32447599

IPAF should receive early treatment for sharing similar clinical characteristics as CTD-ILD: a report from 273 Chinese patients.

Ying Li1, ZhaoHui Zheng1, Qing Han1, ZhiQin Li1, RongHua Xie1, Rui Zhang1, Bei Zhang1, Ping Zhu2.   

Abstract

OBJECTIVES: The clinical characteristics of interstitial pneumonia with autoimmune features (IPAF) and connective tissue disease interstitial lung disease (CTD-ILD) have not been adequately compared. We compared the clinical characteristics of these two conditions and analyzed the changes in lung function before and after treatment of IPAF.
METHODS: A total of 412 patients were enrolled in the study, and their clinical characteristics were assessed. The treatment-related changes in 12 cases of IPAF were analyzed.
RESULTS: Complete clinical data were available for 126 patients with CTD-ILD and 147 with IPAF. All IPAF patients showed autoantibody positivity. The proportion of patients showing extrapulmonary symptoms in the CTD-ILD group was higher than that in the IPAF group (P < 0.05). Patients with IPAF demonstrated lower P(A-a)O2 and higher PaO2 and PaCO2 than those with CTD-ILD (P < 0.05 for all comparisons). Forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO) in IPAF patients were higher than those in CTD-ILD patients (P = 0.023 for FVC; P = 0.011 for DLCO). Among patients with IPAF, only the proportions of honeycombing and nodules were lower than those in CTD-ILD patients (P < 0.05). Both FVC and DLCO values increased after treatment in patients with IPAF (P < 0.05).
CONCLUSION: IPAF showed autoantibody positivity and similar computed tomography (CT) findings as CTD-ILD, and lung function in patients with IPAF improved after immunosuppressive treatment, indicating that IPAF should receive attention and early immunosuppressive treatment like CTD-ILD, even though IPAF exhibits no extrapulmonary symptoms. Key Points • Clinical characteristics of IPAF.

Entities:  

Keywords:  Clinical characteristics; Connective tissue disease; Interstitial lung disease; Interstitial pneumonia with autoimmune features

Mesh:

Year:  2020        PMID: 32447599     DOI: 10.1007/s10067-020-05149-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  2 in total

1.  Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features.

Authors:  Jingxian Wang; Peiyan Zheng; Zhifeng Huang; Huimin Huang; Mingshan Xue; Chenxi Liao; Baoqing Sun; Nanshan Zhong
Journal:  BMC Pulm Med       Date:  2020-12-02       Impact factor: 3.317

Review 2.  Recent advances in the diagnosis and management of interstitial pneumonia with autoimmune features: the perspective of rheumatologists.

Authors:  Hong Ki Min; Se-Hee Kim; Sang-Heon Lee; Hae-Rim Kim
Journal:  Korean J Intern Med       Date:  2021-02-08       Impact factor: 2.884

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.